US Patent

US10028925 — Liquid dosage forms of sodium naproxen

Method of Use · Assigned to Patheon Softgels Inc · Expires 2026-03-03 · 0y expired

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects liquid dosage forms of sodium naproxen in soft gel capsules.

USPTO Abstract

Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.

Drugs covered by this patent

naproxen-sodium (NAPROXEN SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1731`	—	naproxen-sodium

Patent Metadata

Patent number: US10028925
Jurisdiction: US
Classification: Method of Use
Expires: 2026-03-03
Drug substance claim: No
Drug product claim: Yes
Assignee: Patheon Softgels Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.